SynthesisEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
A systematic review of data on the resistance of uropathogens to sulopenem.
Synthesis in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSulopenem is a recently approved penem (in its oral formulation) by the Food and Drug Administration (FDA) for adult women with uncomplicated urinary tract infections that have limited or no other available therapeutic options. In this systematic review, we evaluated sulopenem resistance in Gram-negative and Gram-positive pathogens using the most recent published data.
methodsSix resources, including Embase, Google Scholar, PubMed Central (PMC), PubMed, Scopus, and Web of Science, were used to identify relevant articles. The minimum inhibitory concentration (MIC) range, MIC50, MIC90, and resistance proportions were evaluated.
resultsAfter screening 477 articles, 11 studies were selected, comprising 9,768 isolates. Sulopenem demonstrated favorable activity against Enterobacterales and Proteus mirabilis, as well as good activity against methicillin-susceptible Staphylococcus aureus and Klebsiella species. Limited activity was observed against Enterococcus species, and no activity against methicillin-resistant S. aureus and Pseudomonas aeruginosa. Regarding Escherichia coli, the maximum MIC was < 0.25 mg/L in 5 of 9 (56%) studies with available data. For Klebsiella pneumoniae and Proteus mirabilis, the maximum MIC was < 0.5 mg/L in 5 of 8 (63%) studies with available data. DISCUSSION: Sulopenem showed activity against various pathogens, including both Gram-negative and Gram-positive bacteria. However, these observations were primarily based on MIC data for sulopenem against these pathogens. Further studies assessing the potential emergence of resistance to sulopenem using the recently published FDA susceptibility breakpoints would provide important epidemiological data of clinical relevance.
Indexed as
Identifiers
41703210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.